Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma will front $80 million, an additional $20 million equity investment and up to $660 million in development milestones for rights to CoMentis' beta-secretase inhibitor program for Alzheimer's disease
Advertisement

Related Content

Alzheimer's Partnerships: Sharing Risks, Chasing Potentially Huge Rewards
Alzheimer's Partnerships: Sharing Risks, Chasing Potentially Huge Rewards
Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline
Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline
Yen’s Rise, Slow New Drug Launches Cloud Astellas’ 2008 Earnings Outlook
Yen’s Rise, Slow New Drug Launches Cloud Astellas’ 2008 Earnings Outlook
Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08
Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08
Rethinking Alzheimer's: Mapping Out an Approval Process
Advertisement
UsernamePublicRestriction

Register

SC068295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel